Drug
Vemurafenib clinical trials
Also written Zelboraf, RO5185426 and PLX4032.
- studies test it
- 121
- open now
- 16
- in phase 3
- 8
- first study started
- 2006
Keep track of what changes. Save the Vemurafenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Zelboraf
- 47
Studies by the year they started
121 studies that test it; most in 2013 (23)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 9 |
| 2012 | 12 |
| 2013 | 23 |
| 2014 | 11 |
| 2015 | 9 |
| 2016 | 7 |
| 2017 | 9 |
| 2018 | 10 |
| 2019 | 1 |
| 2020 | 7 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 46
- Phase 2
- 69
- Phase 3
- 8
- Phase 4
- 2
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 66
Who runs them
Industry 49 · Other 72
Hoffmann-La Roche (32) · Memorial Sloan Kettering Cancer Center (6) · Shanghai Kechow Pharma, Inc. (5) · National Cancer Institute (NCI) (4) · Genentech, Inc. (4) · M.D. Anderson Cancer Center (3) · Fondazione Melanoma Onlus (3) · H. Lee Moffitt Cancer Center and Research Institute (3)
Often tested with
Tested in the same studies.
Cobimetinib (35) · Atezolizumab (17) · Alectinib (12) · Trastuzumab (10) · Entrectinib (9) · Palbociclib (9) · Pertuzumab (9) · Olaparib (8)
Studies
Open first, then newest update. How each study uses Vemurafenib is read from its arms, and is right about nine times in ten.
Testing it · 121
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Genentech, Inc.NCT04302025Written as Vemurafenib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06561360Written as Vemurafenib
- Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerRecruitingPhase 3Shanghai Kechow Pharma, Inc.NCT06008119Written as Tunlametinib plus Vemurafenib
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingPhase 2City of Hope Medical CenterNCT06440850Written as Vemurafenib
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT05768178Written as Vemurafenib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Vemurafenib 240 MG
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Vemurafenib
- Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal CancerRecruitingPhase 2Shanghai Changzheng HospitalNCT06603376Written as FOLFIRI + Vemurafenib + Cetuximab
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Vemurafenib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Vemurafenib and Cobimetinib (combination treatment)
- Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyNot yet recruitingPhase 2Shanghai Kechow Pharma, Inc.NCT05900219Written as HL-085+Vemurafenib
- Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)RecruitingPhase 2Shanghai Kechow Pharma, Inc.NCT05233332Written as Vemurafenib
- A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 MutationRecruitingPhase 1Shanghai Kechow Pharma, Inc.NCT03781219Written as Vemurafenib
- HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K MutationRecruitingPhase 2Shanghai Kechow Pharma, Inc.NCT05263453Written as Vemurafenib
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma PatientsRecruitingPhase 1/2University of LouisvilleNCT01638676Written as Vemurafenib
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingPhase 3Hoffmann-La RocheNCT03768063Written as Vemurafenib
- Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03224767Written as Vemurafenib
- Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisActive, not recruitingPhase 2Anna RaciborskaNCT04943198Written as Vemurafenib
- Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01709292Written as Vemurafenib (All Groups)
See all 121 studies that test Vemurafenib →
Given in every arm · 15 — Vemurafenib is usual care beside what is tested
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Vemurafenib
- Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03181100Written as Vemurafenib
- A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaCompletedPhase 3Hoffmann-La RocheNCT02908672Written as Vemurafenib
- Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain MetastasesWithdrawnPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT02145910Written as Vemurafenib
- LY3022855 With BRAF/MEK Inhibition in Patients With MelanomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03101254Written as Vemurafenib
- Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal CancerStatus unknownPhase 1West China HospitalNCT05019534Written as Vemurafenib Oral Tablet [Zelboraf]
- A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaCompletedPhase 3Hoffmann-La RocheNCT01689519Written as Vemurafenib
- Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsCompletedPhase 1M.D. Anderson Cancer CenterNCT01531361Written as Vemurafenib
- A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic MelanomaCompletedPhase 1Genentech, Inc.NCT01656642Written as Vemurafenib
- Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT01596140Written as Vemurafenib
- Systemic Therapy With Interferon, Interleukin-2 and BRAF InhibitorCompletedPhase 1M.D. Anderson Cancer CenterNCT01603212Written as Vemurafenib
- The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With MelanomaTerminatedPhase 2Georgetown UniversityNCT01813214Written as Vemurafenib
- Study of PX-866 and Vemurafenib in Patients With Advanced MelanomaTerminatedPhase 1/2Cascadian Therapeutics Inc.NCT01616199Written as vemurafenib
- A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersCompletedPhase 2Hoffmann-La RocheNCT01524978Written as vemurafenib
- Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaTerminatedPhase 2Melanoma Research Foundation Breakthrough ConsortiumNCT01495988Written as Vemurafenib
As the comparator · 2 — what is tested is compared with Vemurafenib
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaCompletedPhase 3PfizerNCT01909453Written as vemurafenib
- Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous MelanomaCompletedPhase 3Novartis PharmaceuticalsNCT01597908Written as Vemurafenib
Codes
What other systems call Vemurafenib · ClinicalTrials.gg INT006733
- MeSH (NLM) D000077484VemurafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 207SMY3FQTVEMURAFENIBConfirmed FDA, NLM, Wikidata
- RxNorm 1147220Confirmed FDA, Wikidata
- Wikidata Q423111vemurafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64768VemurafenibOne source FDA
- DrugBank DB08881One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077484 | Vemurafenib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 207SMY3FQT | VEMURAFENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1147220 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423111 | vemurafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64768 | Vemurafenib | One source FDA |
| DrugBank | DB08881 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.